hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.2478/v10007-011-0010-x

International pharmaceutical social risk regulation: An ethical perspective

CAMERON GORDON ; Faculty of Business and Government, University of Canberra, Bruce, ACT 2601 Australia

Puni tekst: engleski, pdf (99 KB) str. 15-23 preuzimanja: 413* citiraj
APA 6th Edition
GORDON, C. (2011). International pharmaceutical social risk regulation: An ethical perspective. Acta Pharmaceutica, 61 (1), 15-23. https://doi.org/10.2478/v10007-011-0010-x
MLA 8th Edition
GORDON, CAMERON. "International pharmaceutical social risk regulation: An ethical perspective." Acta Pharmaceutica, vol. 61, br. 1, 2011, str. 15-23. https://doi.org/10.2478/v10007-011-0010-x. Citirano 21.09.2019.
Chicago 17th Edition
GORDON, CAMERON. "International pharmaceutical social risk regulation: An ethical perspective." Acta Pharmaceutica 61, br. 1 (2011): 15-23. https://doi.org/10.2478/v10007-011-0010-x
Harvard
GORDON, C. (2011). 'International pharmaceutical social risk regulation: An ethical perspective', Acta Pharmaceutica, 61(1), str. 15-23. https://doi.org/10.2478/v10007-011-0010-x
Vancouver
GORDON C. International pharmaceutical social risk regulation: An ethical perspective. Acta Pharm. [Internet]. 2011 [pristupljeno 21.09.2019.];61(1):15-23. https://doi.org/10.2478/v10007-011-0010-x
IEEE
C. GORDON, "International pharmaceutical social risk regulation: An ethical perspective", Acta Pharmaceutica, vol.61, br. 1, str. 15-23, 2011. [Online]. https://doi.org/10.2478/v10007-011-0010-x

Sažetak
Pharmaceutical production and distribution constitute big business. For the companies the rewards can be substantial. Rates of return on drug company investments tend to be higher than many other manufacturing enterprises. But reward is only one side of the story. There is also the issue of social risk, the focus of this article. Social risk for pharmaceutical production is especially pronounced. An ineffective or, worse, dangerous drug, can have dire consequences for the population at large. For this reason, there is elaborate government regulation and oversight of drug safety and risk. These systems, especially in the US and Europe, will be the main focus of this paper. The two systems will be described, and then compared and contrasted in terms of their framing of social risk and actions governments take to limit it. Systems elsewhere, especially in the developing world, are increasing in relative importance and these will be briefly discussed as well. Ethical issues that have arisen in these various systems will be surfaced and analysed. The paper will close with some conclusions and suggestions for further research.

Ključne riječi
risk; externality; pharmaceutical industry; drug regulation; social risk; drug policy; ethics; corporate social responsibility

Hrčak ID: 63381

URI
https://hrcak.srce.hr/63381

[hrvatski]

Posjeta: 885 *